In the US, NovoSeven (coagulation factor viia systemic) is a member of the drug class miscellaneous coagulation modifiers and is used to treat Factor VII Deficiency, Hemophilia A and Hemophilia B.
US matches:
- NovoSeven RT
- Novoseven
- NovoSeven RT injection
- NovoSeven injection
UK matches:
- NovoSeven 1 mg (50 KIU) powder and solvent for solution for injection, NovoSeven 2 mg (100 KIU) powder and solvent for solution for injection, NovoSeven 5 mg (250 KIU) powder and solvent for solution for injection
- NovoSeven 1 mg (50KIU) powder and solvent for solution for injection. NovoSeven 2 mg (100 KIU) powder and solvent for solution for injection. NovoSeven 5 mg (250 KIU) powder and solvent for solution for injection. (SPC)
Ingredient matches for NovoSeven
Coagulation Factor VIIa, Human, recombinant Eptacog Alfa (activated) (a derivative of Coagulation Factor VIIa, Human, recombinant) is reported as an ingredient of NovoSeven in the following countries:
- Australia
- Austria
- Bahrain
- Belgium
- Bosnia & Herzegowina
- China
- Croatia (Hrvatska)
- Cyprus
- Czech Republic
- Denmark
- Finland
- France
- Germany
- Greece
- Hong Kong
- Hungary
- Ireland
- Israel
- Italy
- Japan
- Jordan
- Kuwait
- Luxembourg
- Malaysia
- Mexico
- Netherlands
- New Zealand
- Norway
- Poland
- Romania
- Russian Federation
- Serbia
- Singapore
- Slovakia
- Slovenia
- South Africa
- Sweden
- Switzerland
- Taiwan
- Tunisia
- Turkey
- United Kingdom
- United States
International Drug Name Search
Glossary
SPC | Summary of Product Characteristics (UK) |
Click for further information on drug naming conventions and International Nonproprietary Names.